A nurse-led collaborative care mannequin that built-in cell well being improved total survival and days out of the hospital amongst sufferers with coronary heart failure with lowered ejection fraction (HFrEF) in India, primarily based on findings from the TIME-HF trial introduced at ESC Congress 2026 and simultaneously published in Circulation. Researchers spotlight that this mannequin could function a blueprint for different nations the place entry to care is proscribed.
The trial randomized roughly 1,500 sufferers with HFrEF throughout 22 facilities in India to both the nurse-led intervention program or traditional care and adopted them for as much as two years. The nurse-led illness administration program built-in cell well being and included self-care training, energetic follow-up, and steady outpatient monitoring all through the research interval. The imply age of individuals was 62 years, roughly 78% have been males, 70% had restricted training, 57% lived in rural areas, and all however one accomplished 24 months of follow-up.
General findings confirmed a considerably increased chance of surviving with out hospitalization with the intervention vs. traditional care (84.0% vs. 79.4%; p<0.001). Moreover, there was a 22% discount in deaths at two years with the nurse-led intervention in contrast with traditional care.
“Taken collectively, the info recommend {that a} structured, nurse-coordinated, technology-enabled supply mannequin could provide a sensible technique to enhance coronary heart failure outcomes in routine care,” stated Panniyammakal Jeemon, MD, in presenting the findings. “We consider this mannequin just isn’t solely related to low- and middle-income nations but additionally to different settings world wide the place adherence to guideline-directed medical therapies is suboptimal.”
In a related editorial comment, Rajeev Gupta, MD, PhD, notes that “enhancing adherence to medicines and wholesome existence is a crucial space of investigation in HF, and this research targeted on transitional take care of HF is among the largest with the longest follow-up from South Asia.”
In another editorial comment, Lisa A. Kitko, PhD, RN, highlights the significance of the trial to team-based care, writing, “TIME-HF advances the science of coronary heart failure implementation by connecting a nurse-coordinated collaborative care intervention with adjustments in evidence-based prescribing and subsequent medical outcomes in sufferers with [HFrEF]. Its broader contribution could be the demonstration that nurses, supported by digital instruments and collaborative authority, can function the implementation infrastructure for high-value cardiovascular care.”
Go to ACC’s ESC Congress 2026 coverage page to discover the newest science and key takeaways shaping cardiovascular care.
Key phrases:
ESC Congress, ESC26
